171 related articles for article (PubMed ID: 37230161)
1. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
2. Interaction of psychedelic tryptamine derivatives with a lipid bilayer.
Zohairi F; Khandelia H; Hakami Zanjani AA
Chem Phys Lipids; 2023 Mar; 251():105279. PubMed ID: 36627076
[TBL] [Abstract][Full Text] [Related]
3. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
4. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
5. Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
Barman R; Kumar Bora P; Saikia J; Konwar P; Sarkar A; Kemprai P; Proteem Saikia S; Haldar S; Slater A; Banik D
Phytochemistry; 2024 Feb; 218():113928. PubMed ID: 38035973
[TBL] [Abstract][Full Text] [Related]
6. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
[TBL] [Abstract][Full Text] [Related]
7. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.
Jiang XL; Shen HW; Mager DE; Yu AM
Drug Metab Dispos; 2013 May; 41(5):975-86. PubMed ID: 23393220
[TBL] [Abstract][Full Text] [Related]
9. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.
Uthaug MV; Lancelotta R; van Oorsouw K; Kuypers KPC; Mason N; Rak J; Šuláková A; Jurok R; Maryška M; Kuchař M; Páleníček T; Riba J; Ramaekers JG
Psychopharmacology (Berl); 2019 Sep; 236(9):2653-2666. PubMed ID: 30982127
[TBL] [Abstract][Full Text] [Related]
10. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
11. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
12. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
[TBL] [Abstract][Full Text] [Related]
13. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
[TBL] [Abstract][Full Text] [Related]
14. Concise synthesis of N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine starting with bufotenine from Brazilian Anadenanthera ssp.
Moreira LA; Murta MM; Gatto CC; Fagg CW; dos Santos ML
Nat Prod Commun; 2015 Apr; 10(4):581-4. PubMed ID: 25973481
[TBL] [Abstract][Full Text] [Related]
15. A narrative synthesis of research with 5-MeO-DMT.
Ermakova AO; Dunbar F; Rucker J; Johnson MW
J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
[TBL] [Abstract][Full Text] [Related]
16. Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.
Shen HW; Jiang XL; Yu AM
Bioanalysis; 2009 Apr; 1(1):87-95. PubMed ID: 20523750
[TBL] [Abstract][Full Text] [Related]
17. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.
Kärkkäinen J; Forsström T; Tornaeus J; Wähälä K; Kiuru P; Honkanen A; Stenman UH; Turpeinen U; Hesso A
Scand J Clin Lab Invest; 2005; 65(3):189-99. PubMed ID: 16095048
[TBL] [Abstract][Full Text] [Related]
18. Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the "God Molecule".
Al-Imam A; Motyka MA; Hoffmann B; Magowska A; Michalak M
Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375778
[TBL] [Abstract][Full Text] [Related]
19. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.
Szabo A; Kovacs A; Frecska E; Rajnavolgyi E
PLoS One; 2014; 9(8):e106533. PubMed ID: 25171370
[TBL] [Abstract][Full Text] [Related]
20. Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.
Kalirajan R; Rishabh K; Srikanth J; Niharika M; Preeya N; Rezaul I
Arch Razi Inst; 2023 Oct; 78(5):1603-1614. PubMed ID: 38590677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]